Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722 on ClinicalTrials.gov · last registry update 2026-04-13
An unusually large phase 3: 1,250 participants, more than double the 424 typical for the stage. Its estimated completion date, August 2026, has passed with no update to the record. Primary outcome, as filed: Change from Baseline in Hemoglobin A1c (HbA1c) (%). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P3
- Drug
- semaglutideWegovy, Ozempic, Rybelsus
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 1,250
- Started
- 2024-02-21
- Primary completion
- 2026-08 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from Baseline in Hemoglobin A1c (HbA1c) (%)
Conditions studied
Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.